Jiao Tang

Jiao Tang

Auto-generated profile, based on publicly available information

Jiao Tang

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu, China, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XYXiaojuan Yu
Xiaojuan Yu
XKXiao Ke
Xiao Ke
YTYao Tang
Yao Tang
TTTao Tang
Tao Tang
YNYongbo Ni
Yongbo Ni
YCYu Chuanfei
Yu Chuanfei
Antibody–drug conjugates (ADCs) are a pivotal technology for precision cancer therapy, harnessing the synergistic effects of antibody targeting and toxin delivery. However, traditional ADCs encounter limitations in efficacy that stem from tumor resistance, heterogeneity, and intense target competition. Dual-payload ADCs (DP-ADCs) represent a promising solution to these challenges, as they leverage dual mechanisms of action that mitigate acquired drug resistance and enhance adaptability to tumor heterogeneity. The complex structure of DP-ADCs presents substantial quality control hurdles. In this manuscript, we review the current payload selection and conjugation strategies of DP-ADCs and examine recent advances in quality control research. Specifically, we analyze the analytical challenges related to the quantification of free toxins, the determination of the total antibody content, and the characterization of the drug-to-antibody ratio and its distribution. Ultimately, the aim of this work is to provide valuable guidance for future DP-ADC quality control analyses to facilitate their clinical translation and application.

12 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
XYXiaojuan Yu
Xiaojuan Yu
XKXiao Ke
Xiao Ke
YTYao Tang
Yao Tang
TTTao Tang
Tao Tang
YNYongbo Ni
Yongbo Ni
YCYu Chuanfei
Yu Chuanfei
Antibody–drug conjugates (ADCs) are a pivotal technology for precision cancer therapy, harnessing the synergistic effects of antibody targeting and toxin delivery. However, traditional ADCs encounter limitations in efficacy that stem from tumor resistance, heterogeneity, and intense target competition. Dual-payload ADCs (DP-ADCs) represent a promising solution to these challenges, as they leverage dual mechanisms of action that mitigate acquired drug resistance and enhance adaptability to tumor heterogeneity. The complex structure of DP-ADCs presents substantial quality control hurdles. In this manuscript, we review the current payload selection and conjugation strategies of DP-ADCs and examine recent advances in quality control research. Specifically, we analyze the analytical challenges related to the quantification of free toxins, the determination of the total antibody content, and the characterization of the drug-to-antibody ratio and its distribution. Ultimately, the aim of this work is to provide valuable guidance for future DP-ADC quality control analyses to facilitate their clinical translation and application.